Annexin A5 Inhibits Endothelial Inflammation Induced by Lipopolysaccharide-Activated Platelets and Microvesicles via Phosphatidylserine Binding
Sepsis is caused by a dysregulated immune response to infection and is a leading cause of mortality globally. To date, no specific therapeutics are available to treat the underlying septic response. We and others have shown that recombinant human annexin A5 (Anx5) treatment inhibits pro-inflammatory...
Main Authors: | Brent J. Tschirhart, Xiangru Lu, Janice Gomes, Arundhasa Chandrabalan, Gillian Bell, David A. Hess, Guangxin Xing, Hong Ling, Dylan Burger, Qingping Feng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/16/6/837 |
Similar Items
-
Therapeutic Potential of Annexins in Sepsis and COVID-19
by: Louise Mui, et al.
Published: (2021-09-01) -
Pharmacokinetics of recombinant human annexin A5 (SY-005) in patients with severe COVID-19
by: Brent J. Tschirhart, et al.
Published: (2024-01-01) -
Phosphatidylserine-Exposing Annexin A1-Positive Extracellular Vesicles: Potential Cancer Biomarkers
by: Gloria I. Perez, et al.
Published: (2023-03-01) -
Domain IV of Annexin A5 Is Critical for Binding Calcium and Guarantees Its Maximum Binding to the Phosphatidylserine Membrane
by: Jie Wang, et al.
Published: (2017-12-01) -
Apoptosis, annexin A5 and anti-annexin A5 antibodies in the antiphospholipid syndrome
by: Bećarević Mirjana, et al.
Published: (2013-01-01)